Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.

Guardado en:

Detalles Bibliográficos
Autores principales:	Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7e03180accc34d52b7997deb52cfee5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e03180accc34d52b7997deb52cfee5f
record_format	dspace
spelling	oai:doaj.org-article:7e03180accc34d52b7997deb52cfee5f2021-12-02T15:38:33ZBrigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer10.1038/ncomms147682041-1723https://doaj.org/article/7e03180accc34d52b7997deb52cfee5f2017-03-01T00:00:00Zhttps://doi.org/10.1038/ncomms14768https://doaj.org/toc/2041-1723Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.Ken UchiboriNaohiko InaseMitsugu ArakiMayumi KamadaShigeo SatoYasushi OkunoNaoya FujitaRyohei KatayamaNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-16 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ken Uchibori Naohiko Inase Mitsugu Araki Mayumi Kamada Shigeo Sato Yasushi Okuno Naoya Fujita Ryohei Katayama Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
description	Resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer is mediated by the C797S/T790M/activating mutation. Here, the authors identify brigatinib as a potential drug that in combination with anti-EGFR can overcome resistance in mutated cells.
format	article
author	Ken Uchibori Naohiko Inase Mitsugu Araki Mayumi Kamada Shigeo Sato Yasushi Okuno Naoya Fujita Ryohei Katayama
author_facet	Ken Uchibori Naohiko Inase Mitsugu Araki Mayumi Kamada Shigeo Sato Yasushi Okuno Naoya Fujita Ryohei Katayama
author_sort	Ken Uchibori
title	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_short	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_full	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_fullStr	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_full_unstemmed	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
title_sort	brigatinib combined with anti-egfr antibody overcomes osimertinib resistance in egfr-mutated non-small-cell lung cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/7e03180accc34d52b7997deb52cfee5f
work_keys_str_mv	AT kenuchibori brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT naohikoinase brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT mitsuguaraki brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT mayumikamada brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT shigeosato brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT yasushiokuno brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT naoyafujita brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer AT ryoheikatayama brigatinibcombinedwithantiegfrantibodyovercomesosimertinibresistanceinegfrmutatednonsmallcelllungcancer
_version_	1718386182547570688

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Ejemplares similares